NICE rules out abatacept for arthritis patients
26 October 2007
The rheumatoid arthritis (RA) drug abatacept is too expensive to be prescribed on the NHS, according to NICE.
In a draft single technology appraisal of the drug, released today, NICE said abatacept is as effective as the other cytokine inhibitor rituximab for RA, but costs twice as much.
Rituximab was recently approved for use with methotrexate in RA patients RA who fail to respond to other disease-modifying anti-rheumatic drugs (DMARDs).
A NICE spokesperson said: ‘Whilst recognizing the severity of the disease, the committee concluded that based on this evidence, abatacept could not be considered good use of NHS resources.’
Chief executive of the National Rheumatoid Arthritis Society Ailsa Bosworth said: ‘To deny patients abatacept is to deny people with a very aggressive and severe form of RA one more chance at controlling the disease and condemn them to a life of pain and disability.’
rachel.liddle@haymarket.com
Comment below and tell us what you think
Additional Information
Latest jobs Jobs web feed
- 2X Part Time Salaried GPs Deerness Park Medical Centre Competitive, Sunderland Tyne & Wear
- Full time GP partner - Isle of Man Laxey and Village Walk Health Centres Competitive, Isle of Man
- General Practitioner x 2 for MOD, RAF Leuchars, Fife MMP Competitive hourly rates offered, East Coast of Scotland
- Locum GPs Urgently Required OOH's Earn up to £70 per hour!! Merco £70/hour, South East region
- GP Locum in Greater Manchester - Long Term Locum Fresh Medical Recruitment £75 per hour, Greater Manchester
- Opportunity to be Working as a Locum GP in Surrey, Sussex and Kent with Capital Locums whenever you want from £72 Capital Group Locums From £72ph, Surrey, Sussex and Kent
Most read
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
